LOINC Code 45252-4: Institutional entry point HIV treatment
45252-4 is a LOINC code used to identify Institutional entry point HIV treatment in laboratory and clinical observation data. You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges. LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Institutional entry point HIV Rx. It is commonly used with the system or sample type Facility.
What is this code?
LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Institutional entry point HIV Rx. It is commonly used with the system or sample type Facility.
When is it used?
- Used in lab systems, EHRs, and clinical data exchange.
- May identify a test, observation, survey item, or clinical document request rather than a diagnosis.
- Status: ACTIVE
- Method: Reported
What it does not mean
- The code identifies the observation or test, not the actual result.
Key facts
- Institutional entry point HIV treatment
- Institutional entry point HIV Rx
- The type of institutional setting in which the person started anti-retroval therapy (ART).
- AIDS; Anti-retroviral therapy; ART; Fclty; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Inst entry point HIV Rx; Nominal; Point in time; Random; Treatment; Typ
Where you may see this code
You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges.
Common synonyms
Frequently asked questions
About this content
This page is prepared by HealthAssure's clinical team using official coding standards from LOINC. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.